Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

Drugs in R and D

Volumn 16, Issue 2, 2016, Pages 217-227

  Kalberg, Chris ^a   O’Dell, Dianne ^a   Galkin, Dmitry ^a   Newlands, Amy ^b   Fahy, William A ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDACATEROL; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; UMECLIDINIUM PLUS VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; DRUG COMBINATION; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE; QUINUCLIDINE DERIVATIVE; UMECLIDINIUM; VILANTEROL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRY POWDER INHALER; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEADACHE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; MALE; MORNING DOSAGE; MULTICENTER STUDY; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE ASSESSMENT; RHINOPHARYNGITIS; SCORING SYSTEM; SHOCK; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX; VITAL SIGN; AGED; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; QUINUCLIDINES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84962324214     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-016-0131-2     Document Type: Article

References (25)

1. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, 2015. Available at http://www.goldcopd.com. Accessed on 03 Dec 2015.
2. Dransfield MT, Bailey W, Crater G, Emmett A, O’Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20:46–53.
3. Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75:61–74.
4. GSK. Anoro™ ELLIPTA™ prescribing information, 2014. Available at https://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDF. Accessed on 03 Dec 2015.
5. GSK. Anoro™ ELLIPTA™ summary of product characteristics, 2014. Available at http://www.medicines.org.uk/emc/medicine/28949#INDICATIONS. Accessed on 03 Dec 2015.
6. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538–46.
7. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472–86.
8. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752–60.
9. ® prescribing information, 2014. Available at http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva/Spiriva.pdf. Accessed on 03 Dec 2015.
10. ® summary of product characteristics, 2015. Available at https://www.medicines.org.uk/emc/medicine/10039. Accessed on 03 Dec 2015.
11. Novartis. Arcapta™ Neohaler™ prescribing information, 2011. Available at https://www.pharma.us.novartis.com/product/pi/pdf/arcapta.pdf. Accessed on 03 Dec 2015.
12. ® summary of product characteristics, 2014. Available at https://www.medicines.org.uk/EMC/medicine/23260/SPC/Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder,+hard+capsules/. Accessed on 03 Dec 2015.
13. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–54.
14. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:155–62.
15. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH]. ICH harmonised tripartite guideline: guideline for good clinical practice E6(1), 1996 (cited 2013 May). Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Accessed on 03 Dec 2015.
17. World Medical Association [WMA]. WMA Declaration of Helsinki—ethical principles for medical research involving human subjects, 2013 [cited 2013 May]. Available at http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed on 03 Dec 2015.
18. Celli BR. MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–46.
19. Mahler DA, Witek TJ Jr. The MCID of the Transition Dyspnea Index is a total score of one unit. COPD. 2005;2:99–103.
20. Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2:75–9.
21. Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1:19–21.
22. Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.
23. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010;11:135.
24. Lewis JA, Machin D. Intention to treat—who should use ITT? Br J Cancer. 1993;68:647–50.
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH]. ICH harmonised tripartite guideline: statistical principles for clinical trials E9, 1998. Available at http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/statistical-principles-for-clinical-trials.html. Accessed on 03 Dec 2015.